Cardiovascular diseases are increasingly recognized as late effects of Hodgkin lymphoma (HL) treatment. The purpose of this study was to identify the risk factors for coronary heart disease (CHD) and to quantify the effects of radiation dose to the heart, chemotherapy, and other cardiovascular risk factors.
INTRODUCTION
Hodgkin lymphoma (HL) treatment has improved over recent decades, leading to a 10-year survival rate of more than 80%. 1 However, radiotherapy and chemotherapy are associated with increased cardiovascular morbidity and mortality in long-term survivors. [2] [3] [4] [5] [6] [7] Although radiation doses and target volumes have been reduced over the past decades, mediastinal radiotherapy is still indicated for a substantial proportion of patients, 8, 9 which may result in considerable radiation exposure of the heart.
Few studies have examined the dose-response relationship for cardiac radiation and risk of coronary heart disease (CHD) after radiotherapy. A recent study by Darby et al 10 showed a linear doseresponse relationship between radiation dose to the heart and CHD risk in breast cancer survivors for a relatively low range of mean heart dose (MHD) (range, 0.03-27.7 Gy; average, 5 Gy). The shape of the dose-response relationship has not been studied in HL patients, who generally receive much higher MHDs and are usually younger at diagnosis than breast cancer patients.
Schellong et al 11 and Mulrooney et al 12 observed an association between cardiovascular diseases and prescribed mediastinal radiation dose and MHD among childhood HL (and other cancer) survivors; however, the shape of the radiation dose-response relationship and excess relative risks (ERRs) were not described.
In addition to the shape of the dose-response relationship, the roles of established cardiovascular disease risk factors and lifestyle on CHD risk have rarely been studied among HL survivors. 4, 5, 13 Therefore, the aim of this study was to assess the shape of the doseresponse curve for cardiac radiation dose and the risk of CHD in adolescent and adult HL survivors and to investigate the role of chemotherapy, lifestyle, and other established cardiovascular disease risk factors.
PATIENTS AND METHODS

Study Population
We conducted a nested case-control study in an existing cohort (N = 2,617) of HL survivors treated in the Netherlands between 1965 and 1995. The cohort was derived from hospital-based cancer registries of four large university hospitals and one cancer center. Details on patient selection and data collection have been published previously. 2,7,12,14-17 Patients were eligible for this study if (1) they survived $ 5 years after HL diagnosis; (2) they were diagnosed with HL before the age of 51 years; (3) HL was their first primary malignancy, except for nonmelanoma skin cancer or carcinoma in situ of the cervix uteri or the breast; and (4) radiotherapy for HL was the only radiotherapy given to the neck or trunk before the cutoff date, which was defined as the date of CHD for the cases or the date of HL diagnosis plus a time interval equal to the interval from the date of HL diagnosis to the date of CHD diagnosis of the corresponding case for matched controls.
Cases and Controls
Cases (n = 325) were patients who developed CHD in the form of either symptomatic myocardial infarction or angina pectoris requiring intervention (Common Terminology Criteria for Adverse Events, version 4.0, grade $ 2; Appendix Text A1, online only) 18 as their first clinically significant heart disease. Cases were identified from medical records or postal questionnaires completed by their general practitioners. Follow-up was complete up to October 2013. For each case with CHD, we attempted to select four controls from the cohort, individually matched on sex, age at HL diagnosis (# 1 year), and date of HL diagnosis (# 3 years). Controls had to be free of any cardiac disease grade $ 2 at the cutoff date. In total, 1,204 controls were matched to the cases.
Data Collection
Detailed information on treatment (including radiation doses and fields and cumulative doses of cytotoxic drugs), medical history, medication use, smoking, and established cardiovascular risk factors at both diagnosis of HL and during follow-up was collected from medical records and radiation charts. In addition, a questionnaire on established cardiovascular risk factors and lifestyle was mailed to all patients still alive in 2013 (n = 475) in three of the five centers (response rate, 70%). Patients were defined as having a risk factor when the risk factor concerned was diagnosed before CHD or the cutoff date. The ethics review board of the Netherlands Cancer Institute approved this study.
Mean Heart Dose
The MHD was assessed using the percentage of cardiac volume within field (%CVWF) method 19 and converted to equivalent dose in 2-Gy fractions (EQD2). 20 We recently showed that this method gives reliable MHD estimates for our patient population and compares well with MHD based on computed tomography (CT)-based dosimetry. 19 We outlined the cardiac contour on the HL simulation radiographs to obtain the %CVWF. Additional details can be found in Appendix Text A2.
When original radiotherapy charts were unavailable, information about radiotherapy, including dates, anatomic areas, dose, fractionation, and treatment energy, was abstracted from clinical notes. We assigned an average %CVWF to radiation-treated patients for whom no simulation radiographs were available and an average prescribed dose to patients for whom no prescribed dose was available (n = 473, including 105 cases), on the basis of hospital, treatment period, and sex.
Statistical Analysis
Odds ratios for CHD for different levels of each factor were calculated using conditional logistic regression on sets of individual cases and their matched controls, and were interpreted as rate ratios (RRs). The Wald method was used to calculate 95% CIs for factors with two levels. The amount of information in each category, including the reference category (so-called floating absolute risks), was used to calculate 95% CIs for factors with more than two levels. 21 Multivariable regression was used to assess and control for confounding and to evaluate interactions between radiation dose and other factors.
The dose-response relationship was estimated by modeling the CHD rate as K m (1 + bd), where K m is a constant specific to each matched set, b is the ERR of CHD per unit increase in dose, and d is the MHD of an individual patient. Nonlinearity was evaluated by including an exponential term: K m [1 + bd$exp(dd)]. Goodness of fit was assessed by likelihood ratio tests. Interactions were evaluated using interaction terms and likelihood ratio tests. Approximate cumulative incidence of CHD for categories of MHD, with other heart disease or death as a competing risk, was estimated from CHD RRs together with the cumulative risk of CHD for the entire cohort, assuming that the distribution of all individuals in the cohort across the dose categories was equal to that for the control patients.
Significance tests were two-sided and P # 0.05 was considered to indicate statistical significance. Analyses were performed using STATA statistical software (version 13.0; STATA, College Station, TX) and Epicure (version 1.8; Hiro Soft International Inc, Seattle WA).
RESULTS
Characteristics of the 325 cases and 1,204 controls are described in Table 1 . The median age of patients was 32.2 years (interquartile range [IQR], 24.4 to 39.6) at the time of HL diagnosis, and the median interval between HL and CHD was 19.0 years (IQR, 13.9 to 25.2). Myocardial infarction was diagnosed in 185 patients; angina pectoris requiring intervention was diagnosed in 140 patients (Appendix Table A1 ). In total, 169 of 325 cases died, 42.6% from a cardiovascular disease, after a median follow-up period of 6.0 years after their first CHD (Appendix Table A1 ). Thirty-one patients died of their first CHD incident within a week.
Radiotherapy
Ninety-one percent of the cases had received mediastinal radiotherapy, given through parallel-opposed fields, compared with 79% of the controls (Table 1 ). Mediastinal radiation therapy was associated with a 2.63-fold increased risk of CHD (95% CI, 1.74 to 3.99; Table 2 ). Para-aortic radiotherapy, with or without splenic radiation, was not associated with CHD risk (RR, 0.99; 95% CI, 0.76 to 1.28).
The average MHD was 22.0 Gy for cases and 20.4 Gy for controls ( Table 1) . A linear radiation dose-response relationship best described the data, and no significant deviation from linearity was observed (P exponential-term = .356). The ERR for CHD increased by 7.4% per Gy (95% CI, 3.3% to 14.8%; Fig 1) , resulting in a 1.74-fold increased risk at a MHD of 10 Gy (95% CI, 1.33 to 2.48) and a 2.48-fold increased risk at a MHD of 20 Gy (95% CI, 1.66 to 3.96). The approximate 25year cumulative CHD incidence was 4.1% for patients with a MHD of 0 Gy, 9.4% for patients with a MHD of 15 to 20 Gy, and 12.6% for patients with a MHD of $ 25 Gy (Fig 2) . Results were similar when we only included patients for whom the MHD was known (Appendix Table A2 ). Cases had a median %CVWF of 66%, compared with 64% for controls. Variation in %CVWF was limited, with interquartile ranges of 57% to 71% and 55% to 70%, respectively ( Table 1) .
Other Treatment-Related Risk Factors
Chemotherapy was not associated with CHD risk (RR, 0.87; 95% CI, 0.67 to 1.13), nor were anthracycline-containing chemotherapy (RR, 1.11, 95% CI, 0.76 to 1.62) or vincristinecontaining chemotherapy (RR, 0.86; 95% CI, 0.66 to 1.13), after accounting for mediastinal radiotherapy. Splenectomy also did not affect CHD risk (RR, 0.91; 95% CI, 0.68 to 1.22; Table 2 ).
Patient-Related Risk Factors
Twenty-five percent of cases had at least one classic cardiovascular risk factor (diabetes mellitus, hypercholesterolemia, or hypertension) diagnosed before the diagnosis of CHD (Table 1) . Only hypertension (RR, 1.85; 95% CI, 1.28 to 2.66) and the presence of at least one risk factor (RR, 1.59; 95% CI, 1.17 to 2.19) were associated with an increased risk of CHD (Table 3 ). When risk factors were taken into account in a less conservative manner, that is, by also including risk factors that were diagnosed around the time of CHD diagnosis or cutoff date, not only hypertension but also diabetes mellitus and hypercholesterolemia were associated with a significantly increased risk of developing CHD (Appendix Table A3 ). Obesity at the time of CHD diagnosis or the cutoff date was associated with an increased risk of CHD as well (RR, 1.64; 95% CI, 1.24 to 2.16). Whereas ever smoking was not associated with CHD risk, smoking within 5 years before a diagnosis of CHD or the cutoff date was associated with an increased risk of CHD (RR, 1.56; 95% CI, 1.13 to 2.15; Table 3 ). Patients with a high level of physical activity at the time of the follow-up questionnaire (. 3 h/wk of walking, cycling, or sports) had a considerably lower risk of developing CHD than did patients who were inactive (, 1 h/wk; RR, 0.52; 95% CI, 0.32 to 0.83; Table 3 ). Also, a first-degree family history of CHD was an independent risk factor for CHD (RR, 2.87; 95% CI, 1.41 to 5.88; Table 3 ).
Interactions With Radiation
We found no evidence for statistically significant modification of the effect of MHD on CHD risk by chemotherapy, sex, cardiovascular disease risk factors, and recent smoking at HL diagnosis (Appendix Table A4 ). ERRs seemed to be highest in the lowest tertile of age at HL diagnosis (ERR ,27.5years , 20.0%/Gy; 95% CI, 5.4% to 70.5%) and decreased for the middle (ERR 27.5-36.4years , 8.8%/Gy; 95% CI, 2.6% to 22.9%) and third tertile (ERR 36.5-50.9years , 4.2%/Gy; 95% CI, 0.6% to 11.1%), although this difference was not statistically significant (P interaction = .149). Nevertheless, due to the lower background risk in patients treated at a young age, this higher relative risk did not materialize in a higher cumulative incidence at similar followup intervals after treatment (Fig 3) .
DISCUSSION
To our knowledge, this study shows for the first time a linear doseresponse relationship for MHD and the risk of CHD in 5-year survivors of HL. The overall risk of CHD increased by 7.4% per Gy (95% CI, 3.3% to 14.8%), resulting in a 2.5-fold increased risk at a MHD of 20 Gy. ERRs seemed to decrease with older age at treatment (ERR ,27.5years , 20.0%/Gy; ERR 27.5-36.4years , 8.8%/Gy; ERR 36.5-50.9years , 4.2%/Gy). Although other studies in childhood cancer and breast cancer survivors [10] [11] [12] 22 also showed increased risks with higher radiation exposure of the heart, to our knowledge, our study is the first one with sufficient data to estimate the shape of the doseresponse curve for CHD among adolescent and adult HL survivors. We previously studied the dose-response relationship for valvular heart disease risk after HL and observed an upward curvature with an ERR of 2.5% per Gy for doses less than 30 Gy and 11.2% for doses of 36 to 40 Gy. 23 Because the mechanisms underlying the different types of heart damage after radiation remain unclear, a different pathogenesis may underlie the shape of the dose-response curve for valvular heart disease. Furthermore, uncertainties in assessment of dose to relevant target structures may add to the difference in findings.
Our results are consistent with the results of Darby et al, 10 who also observed a linear dose-response relationship for the risk of major coronary events after radiotherapy for breast cancer. For the patients most comparable with the patients in Darby's article (ie, those treated between 36 and 50 years of age), however, we found an ERR of 4.2%/Gy, whereas Darby et al 10 reported an ERR of 7.4%/Gy. Because the confidence intervals of the ERRs in both studies overlap, it is likely that uncertainties in both data sets partially explain the difference in the magnitude of the ERRs. Our study and Darby's study also differed in terms of study population. Our study included both men and women, patients who were not irradiated, and patients who generally received a higher MHD. Furthermore, although breast cancer survivors frequently received a high dose to a small volume of the heart, HL survivors treated in the past generally received a relatively lower, more homogenous dose to a larger cardiac volume. 24, 25 Although a previous study 12 only showed increased risks of CHD after a MHD exceeding 15 Gy, other studies, 10, 26 including ours, indicate that there is no threshold dose. In future patients, clinicians should carefully weigh the benefits of reducing the MHD against potential risks of higher doses to other organs (ie, lungs and breasts in young females). Importantly, improved radiation policies, including reduction of radiation fields and breath-holding techniques, lead to MHDs of only 4 to 8 Gy. 25, 27, 28 Unfortunately, we were unable to clearly separate the effect of irradiated heart volume from the effects of MHD due to collinearity of the MHD and the %CVWF. However, the variation in irradiated heart volume in our population was limited, both in the total population as well as in specific categories of MHD (data not shown). The variation that occurs in traditional mantle-field irradiation mainly applies to variation in the irradiated volume of the apex, whereas the left main artery generally lies within the radiation field. There remains a gap in knowledge with respect to the role of irradiated heart volume, which should be studied in more depth to fully appreciate the consequences of irradiating a large part of the heart with a lower dose versus irradiating a smaller part of the heart with a high dose.
Neither chemotherapy in general nor specific chemotherapeutic agents were associated with CHD risk. Previously, anthracycline-containing chemotherapy has been associated with heart failure and, recently, with valvular heart disease, 2,5,7,29 but not with CHD. Swerdlow et al 30 previously observed an association between anthracycline-and vincristine-containing chemotherapy and the risk of death from myocardial infarction. We could not confirm these results.
In this study, we showed that hypertension, obesity, and recent smoking are independent risk factors for the development of CHD in HL survivors. Similar results have been published previously for childhood cancer survivors by Armstrong et al, who showed that survivors with one or more risk factors had a higher risk of developing major cardiac events compared with those without risk factors. 31 Myrehaug et al 5 found that having risk factors such as diabetes or a history of smoking were predictive for cardiac hospitalization in adult HL survivors. Because of the design of our study (case-control rather than prospective follow-up), we could not adequately examine the temporal relation between cardiovascular risk factors and development of CHD. However, our NOTE. Patients were classified as having a risk factor if these were mentioned in the medical record or questionnaires and diagnosed before coronary heart disease/ cutoff date. If no risk factors were ever mentioned, patients were classified as not having a risk factor. Boldface indicates statistically significant RRs. Abbreviations: BMI, body mass index (kg/m 2 ); HL, Hodgkin lymphoma; RR, rate ratio. *Adjusted for mediastinal radiotherapy and the other risk factors in case of separate estimates for diabetes mellitus, hypertension, hypercholesterolemia, and obesity.
†Analyzed unconditionally on a subpopulation of patients who filled in the risk factor questionnaire (84 patients and 158 individual controls), adjusted for the matching factors.
‡P for trend. §Family history based on (medical) first-degree family members (father, mother, brother, sister, son, or daughter). analyses, excluding risk factor information obtained around CHD diagnosis or corresponding cutoff date for controls, show that hypertension is an important risk factor for CHD. Additional analyses also including risk factors diagnosed around the time of CHD diagnosis or corresponding cutoff date showed that not only hypertension, but also hypercholesterolemia and diabetes are associated with an increased risk of CHD, but this observation may result from rigorous assessment of CHD risk factors at CHD diagnosis in cases and not in controls.
To our knowledge, we are the first to show that higher current physical activity levels may decrease CHD risk in adult HL survivors. Jones et al 32 recently found a lower risk of treatmentrelated cardiac events in childhood cancer survivors who reported 9 metabolic equivalent-hours per week 21 or more, which is equivalent to approximately 2 to 2.5 hours of cycling or walking, or 1 to 1.5 hours of jogging or running. In this observational study, we could not determine whether the association with CHD was due to a causal effect of exercise or to reverse causation, in which the development of cardiac problems causes individuals to reduce the amount of exercise they perform. A randomized intervention trial is needed to provide more insight into the effects of physical activity on CHD risk in the HL population. Nevertheless, our findings regarding both exercise and cardiac risk factors, in combination with previous evidence regarding cardiac risk factors, underline the importance of risk factor control and maintenance or adoption of a healthy lifestyle after HL treatment.
We only included patients who developed CHD as their first cardiac event to evaluate the direct effect of HL treatment on CHD risk and to avoid confusion with secondary consequences of (treatment of) other heart diseases. In our recent cohort analysis, 7 we did not find different associations between mediastinal radiotherapy and first CHD risk versus any CHD risk.
The use of MHD on the basis of the cardiac volume within the radiation fields might be considered a limitation compared with more advanced dosimetry techniques, such as the use of substitute CT data sets 23 or matched deformable heart models. 33 However, the current method has been shown to be accurate and has practical advantages. 19 Compared with CT-based dosimetry, our method is less time-consuming and no expert knowledge is needed. More importantly, individual size and shape of the heart are taken into account, whereas other dosimetry methods used in retrospective studies on patients treated before the era of CT-based radiotherapy planning generally use one or two standard anatomic patients.
Unfortunately, our dosimetry method does not enable estimation of the radiation dose to the coronary arteries. However, Darby et al 10 did estimate the radiation dose to the left anterior descending coronary artery, but found the MHD to be a better predictor of the rate of major coronary events than the mean dose to the left anterior descending artery, as the dose to the coronary arteries was an uncertain measure. The benefits of the currently applied method therefore outweigh the lack of a dose to specific substructures, especially because the location of the coronary event was often unknown for our cases.
In conclusion, mean radiation dose to the heart is an important risk factor for the development of CHD in HL survivors. To our knowledge, we are the first to show a linear radiation doseresponse relationship for CHD in HL survivors. This knowledge may help clinicians to predict the risk of CHD in HL patients treated today, as well as in survivors, and will assist in defining appropriate follow-up care for HL survivors. Furthermore, clinicians and patients should be aware of the importance of controlling general cardiovascular disease risk factors and maintaining a healthy lifestyle to reduce CHD risk.
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Dosimetry Method
We outlined the cardiac contour on the Hodgkin lymphoma simulation radiographs. The percentage cardiac contour within the field (%CCWF) was estimated by dividing the surface of the cardiac contour within the field by the surface of the total cardiac contour, multiplied by 100. The %CCWF was multiplied by a correction factor of 1.12 to obtain the %CCWF. 19 The prescribed radiation dose to the mediastinum was converted to the equivalent dose in 2-Gy fractions, and the alpha-beta ratio was assumed to be 2 Gy for late cardiac effects. 26 The equivalent dose in 2-Gy was multiplied by the %CCWF to obtain the mean heart dose (MHD) in Gy. The MHD was multiplied by 1.10 or 1.05 for patients who received para-aortic radiotherapy with or without splenic radiotherapy, respectively. 19 Patients who received para-aortic radiotherapy with or without splenic radiotherapy, but no mediastinal radiotherapy, were assigned a MHD of 4 and 2 Gy, respectively, based on previous dosimetric findings. 19 
